XSHE
300942
Market cap512mUSD
May 19, Last price
9.22CNY
1D
-0.86%
1Q
7.58%
IPO
-69.26%
Name
Shenzhen Bioeasy Biotechnology Co Ltd
Chart & Performance
P/E
—
P/S
14.56
EPS
—
Div Yield, %
—
Shrs. gr., 5y
32.46%
Rev. gr., 5y
4.40%
Revenues
254m
-63.01%
Net income
-185m
L
CFO
-37m
L
Dividend
May 31, 20230.0212 CNY/sh
Profile
Shenzhen Bioeasy Biotechnology Co., Ltd. develops and sells rapid testing instruments and reagents in China. The company offers detection equipment for use in the fields of food, agricultural, dairy, meat, aquatic, honey, drug, and public safety, as well as clinical diagnosis. Shenzhen Bioeasy Biotechnology Co., Ltd. was founded in 2007 and is based in Shenzhen, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 254,106 -63.01% | 686,897 14.95% | ||||||
Cost of revenue | 233,352 | 499,238 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | 20,754 | 187,659 | ||||||
NOPBT Margin | 8.17% | 27.32% | ||||||
Operating Taxes | 7,185 | 12,222 | ||||||
Tax Rate | 34.62% | 6.51% | ||||||
NOPAT | 13,569 | 175,437 | ||||||
Net income | (184,908) -322.87% | 82,965 -64.92% | ||||||
Dividends | (12,944) | (99,814) | ||||||
Dividend yield | 0.28% | 1.45% | ||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 23,775 | |||||||
Long-term debt | 356,453 | 134,812 | ||||||
Deferred revenue | 16,543 | 20,325 | ||||||
Other long-term liabilities | 3,024 | 2,080 | ||||||
Net debt | (270,474) | (298,927) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (37,250) | 152,555 | ||||||
CAPEX | (128,644) | |||||||
Cash from investing activities | (66,227) | |||||||
Cash from financing activities | 333,125 | |||||||
FCF | 64,003 | (184,132) | ||||||
| Balance | ||||||||
Cash | 601,777 | 247,451 | ||||||
Long term investments | 25,151 | 210,062 | ||||||
Excess cash | 614,222 | 423,168 | ||||||
Stockholders' equity | 539,304 | 828,825 | ||||||
Invested Capital | 680,108 | 677,483 | ||||||
ROIC | 2.00% | 33.62% | ||||||
ROCE | 1.70% | 17.05% | ||||||
| EV | ||||||||
Common stock shares outstanding | 401,973 | 400,860 | ||||||
Price | 11.69 -31.80% | 17.14 -40.61% | ||||||
Market cap | 4,699,069 -31.61% | 6,870,740 -40.61% | ||||||
EV | 4,428,595 | 6,571,813 | ||||||
EBITDA | 54,233 | 218,020 | ||||||
EV/EBITDA | 81.66 | 30.14 | ||||||
Interest | 10,797 | 4,083 | ||||||
Interest/NOPBT | 52.02% | 2.18% | ||||||